Selective targeting free beta‐2 microglobulin as a promising therapeutic strategy for Alzheimer’s Disease
Mi‐Hyang Cho, Min‐Seok Kim, Seung‐Hwan Han, Yeon‐Seon Mun, Ha‐Lim Song, Na‐Young Kim, Jung‐Su Shin, Dong‐Hou Kim, Seung‐Yong Yoon · 2025
Read Selective targeting free beta‐2 microglobulin as a promising therapeutic strategy for Alzheimer’s Disease by Mi‐Hyang Cho, Min‐Seok Kim, Seung‐Hwan Han, Yeon‐Seon Mun, Ha‐Lim Song, Na‐Young Kim, Jung‐Su Shin, Dong‐Hou Kim, Seung‐Yong Yoon (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11709532.txt.
Description
Mi-Hyang Cho and co-authors test a new antibody approach to Alzheimer's disease in this 2025 paper. Their target is beta-2 microglobulin, a small protein that normally sits on cell surfaces as part of an immune complex. When free in blood and spinal fluid, the protein rises with age and in Alzheimer's patients, and it harms memory.
The team built an antibody, named ADEL-Y03, that binds only the free form of the protein and leaves the surface-bound form alone. In mice, the antibody reversed memory deficits caused by the free protein. In a mouse strain bred to model Alzheimer's, injections lowered the free protein in brain and blood. The treatment also cut beta-amyloid buildup and brain inflammation, two hallmarks of the disease. The authors argue this selective targeting could treat Alzheimer's without weakening normal immune function.
Catalog record
| CREATOR | Mi‐Hyang Cho, Min‐Seok Kim, Seung‐Hwan Han, Yeon‐Seon Mun, Ha‐Lim Song, Na‐Young Kim, Jung‐Su Shin, Dong‐Hou Kim, Seung‐Yong Yoon |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |